Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.05 EUR | -0.09% | -1.64% | +12.07% |
May. 29 | AXA Issues EUR750 Million Senior Notes to Refinance Debt | MT |
May. 29 | AXA: successful placement of a 750 ME bond | CF |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Its low valuation, with P/E ratio at 9.46 and 8.7 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.8 for the current period. Therefore, the company is undervalued.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.07% | 78.88B | B- | ||
+9.44% | 51.46B | B+ | ||
+8.93% | 51.07B | B | ||
+20.90% | 46.59B | B+ | ||
+16.04% | 43.21B | B+ | ||
+23.53% | 39.69B | B | ||
-0.60% | 29.1B | B | ||
-6.79% | 27.94B | B- | ||
-15.80% | 26.05B | A- | ||
+22.84% | 25.35B | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CS Stock
- Ratings AXA